NOVOPHARM MOVING INTO U.S. PRIVATE LABEL BUSINESS WITH GRANUTEC ACQUISITION from Roussel Uclaf Holdings, Toronto-based Novopharm announced on May 25. Terms of the deal were not disclosed. Novopharm predicted that the acquisition would be completed by June 30. Granutec OTC private label sales are expected to reach $ 40 mil. in 1993, up approximately 25% from the $ 32 mil. in sales generated in 1992. Novopharm Chairman and CEO Leslie Dan said that Granutec's headquarters in Wilson, N.C. will "eventually" be converted into Novopharm's U.S. manufacturing base. Novopharm is the leading manufacturer of branded prescription generic drugs in Canada, and the lion's share of the products it sells in the U.S. currently are manufactured in Canada. The company also sells private label OTCs through its Vancouver-based Stanley Pharmaceuticals subsidiary to retail chains in Canada. Privately held Novopharm's sales are currently annualizing at $ 240 mil. (approximately $ 300 mil. [Canadian]). "Our future plans include building new manufacturing facilities in Wilson and enlarging our facilities in Largo, Fla.," Dan said. "This will result in more than [double] the production capacity of the facilities, increased local employment, as well as an expanded market for Novopharm." The company plans to use the new and expanded facilities to manufacture branded generics, private label OTCs and "innovative pharmaceuticals that are currently under development."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.
The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys. Discussions on safety of DMD treatment for non-ambulatory patients is ongoing.
While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.
